Article PDF
REFERENCES
G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413–420 (1995).
C. S. Series. Biopharmaceutics Drug Classification and International Drug Regulation. Seminars and Open Forums, Tokyo, Japan, July 15, 1997; Geneva, Switzerland, May 14, 1996; and Princeton, New Jersey, May 17, 1995.
Guidance for industry, Immediate Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes. November 1995, CDER/FDA.
Guidance for industry, Dissolution Testing of Immediate Release Solid Oral Dosage Forms. August 1997, CDER/FDA.
Guidance for industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. August 2000, CDER/FDA.
H. H. Blume and B. S. Schug. The biopharmaceutics classification system (BCS): Class III drugs-better candidates for BA/BE waiver? Eur. J. Pharm. Sci. 9:117–121 (1999).
J. B. Dressman. Physiological aspects of the design of dissolution tests. In G. L. Amidon, J. R. Robinson, and R. L. Williams (eds.), Scientific Foundations for Regulating Drug Product Quality, AAPS Press, 1997 pp. 155–168.
L. X. Yu, E. Lipka, J. R. Crison, and G. L. Amidon. Transport approaches to modeling the biopharmaceutical design of oral drug delivery systems: Prediction of intestinal drug absorption. Adv. Drug Deliv. Rev. 19:359–376 (1996).
R. L. Oberle and G. L. Amidon. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; An explanation for the double peak phenomenon. J. Pharmacokinet. Biopharm. 15:529–544 (1987).
R. Lobenberg and G. L. Amidon. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 50:3–12 (2000).
D. Fleisher, C. Li, Y. Zhou, L.-H. Pao, and A. Karim. Drug, meal, and formulation interactions influencing drug absorption after oral administration. Clin. Pharmacokinet. 36:233–254 (1999).
L. X. Yu, A. S. Carlin, and A. S. Hussain. Feasibility studies of intrinsic dissolution rate as an alternative method to determine BCS solubility membership. AAPS annual meeting (2000).
L. X. Yu. An integrated absorption model for determining dissolution, permeability, and solubility limited absorption. Pharm. Res. 16:1884–1888 (1999).
L. X. Yu, A. Bridgers, J. Polli, A. Vickers, S. Long, A. Roy, R. Winnike, and M. Coffin. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm. Res. 16:1812–1817 (1999).
J. E. Polli and M. J. Ginski. Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities. Pharm. Res. 15: 47–52 (1998).
Guidance for industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. October 2000, CDER/FDA
V. H. L. Lee. Membrane transporters. Eur. J. Pharm. Sci. 11:S41–S50 (2000).
V. J. Wacher, L. Salphati, and L. Z. Benet. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 46:89–102 (2001).
K. M. Koch, A. F. Parr, J. J. Tomlinson, E. P. Sandefer, G. A. Digenis, K. H. Donn, and J. R. Powell. Effect of sodium pyrophosphate on ranitidine bioavailability and gastrointestinal transit time. Pharm. Res. 10:1027–1030 (1993).
D. A. Adkin, S. S. Davis, R. A. Sparrow, P. D. Huckle, A. J. Yu et al. 924 Phillips, and I. R. Wilding. The effects of pharmaceutical excipients on small intestinal transit.Br. J. Clin. Pharmacol. 39:381–387 (1995).
B. J. Aungst. Intestinal permeation enhancers. J. Pharm. Sci. 89: 429–442 (2000).
B. D. Rege, L. X. Yu, A. S. Hussain, and J. E. Polli. Effect of common excipients on Caco-2 transport of low permeability drugs. J. Pharm. Sci. 90:1776–1786 (2001).
L. X. Yu, C. D. Ellison, D. P. Conner, L. J. Lesko, and A. S. Hussain. Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs. {tiPharm. Sci.} 3:article 24, (2001).
W. L. Chiou, S. M. Chung, T. C. Wu, and C. Ma. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther. 39:93–101 (2001).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yu, L.X., Amidon, G.L., Polli, J.E. et al. Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions. Pharm Res 19, 921–925 (2002). https://doi.org/10.1023/A:1016473601633
Issue Date:
DOI: https://doi.org/10.1023/A:1016473601633